Key Highlights

● Summit Therapeutics shares soared on September 29, 2026, closing at $17.96 after AstraZeneca agreed to a $2 billion Equity investment.

● The Investment is through convertible preferred stock at $18.36 per common share and includes a clinical collaboration on cancer studies.

● AstraZeneca is not licensing ivonescimab, so Summit keeps full Economics of its lead drug in its territories.

● Healthcare stocks struggled, and the S&P 500 slipped 12.85 points to 7,670.84 as the Russell 2000 also finished lower.

Summit Therapeutics Inc. (NASDAQ:SMMT) soared on Tuesday, September 29, 2026, after one of the world's biggest drugmakers put $2 billion behind it. The stock closed at $17.96. Sources differed on the size of the gain, with readings taken at different times of day, but all agreed on the direction.

The Deal

AstraZeneca is making a $2 billion strategic equity investment in Summit through convertible preferred stock priced at $18.36 per common share. The agreement also includes a clinical collaboration on cancer studies. AstraZeneca is not licensing Summit's lead drug. Stifel analysts said there is no license and nothing else sold but stock, so Summit keeps full ivonescimab economics in its territories. BMO Capital Markets said the deal creates a meaningful strategic position without acquiring the company or licensing ivonescimab outright at this stage.

Why It Matters

Ivonescimab is an experimental bispecific antibody designed to block two targets at once, PD-1, a checkpoint that tumors use to evade the immune system, and VEGF, a protein that helps tumors grow blood vessels. Late-stage cancer trials are expensive, and a company with a single major asset often faces raising money by selling new shares or licensing away part of its drug's value. A $2 billion cash injection reduces that pressure while leaving Summit's commercial rights intact.

Convertible Preferred Explained

Convertible preferred stock is equity that can later be converted into common shares at a set price, here $18.36. The conversion price sat above where Summit's shares closed on Tuesday. A clinical collaboration means the two companies will work together on studies, giving Summit access to a large partner's development experience.

A Rare Bright Spot

Summit's jump came on a day when healthcare stocks struggled. The S&P 500 closed at 7,670.84, down 12.85 points, and the Dow Jones Industrial Average closed at 51,349.92, down 131.59 points. The Nasdaq Composite ended little changed at 26,797.54. The Russell 2000 finished lower. Elsewhere in biotech, Iovance Biotherapeutics rallied after raising its Revenue guidance, while uniQure tumbled after new data on its Huntington's disease gene therapy.

Rates and Upcoming Releases

Long-term Treasury yields pressured stocks through the session, with the 30-year yield at its highest since 2002. The Conference Board's index of consumer confidence slid to 81.9, a 12-year low, from 88.6 the month before. August PCE Inflation and the third estimate of GDP arrive on Wednesday, September 30, and the September jobs report follows on Friday, October 2, with about 95,000 jobs expected.